Takeda Pharmaceutical Company Limited
NYSETAK cost to borrow surges 190% in one week to 0.61%, though still remains at low levels historically.
TAK heads into its July 30 earnings release with options positioning at its most aggressively bullish in a year. The clearest signal is in the options market. The put/call ratio has collapsed to 0.0085 — near the…
TAK heads into its June 24 results with the options market flashing the most defensive signal of the past year. The clearest story is in options positioning. The put/call ratio jumped to 2.02 on June 18 — four standard…
Snapshot as of 7 Aug 2026
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TAK — free to start on ORTEX.
Sign up for free →Open TAK on ORTEX